Editas Medicine Inc [EDIT] stock prices are up 4.99% to $5.47 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The EDIT shares have gain 2.24% over the last week, with a monthly amount drifted -20.38%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Editas Medicine Inc [NASDAQ: EDIT] stock has seen the most recent analyst activity on October 24, 2023, when Citigroup upgraded its rating to a Buy but kept the price target unchanged to $11 for it. Previously, JP Morgan upgraded its rating to Neutral on October 18, 2023, and kept the price target unchanged to $8. On October 17, 2023, downgrade downgraded it’s rating to Neutral. Stifel upgraded its rating to a Buy and increased its price target to $17 on September 29, 2023. Raymond James upgraded its rating to a Outperform but $17 remained the price target by the analyst firm on June 12, 2023. Cantor Fitzgerald started tracking with a Overweight rating for this stock on February 01, 2023, and assigned it a price target of $15. In a note dated December 13, 2022, Citigroup initiated an Neutral rating and provided a target price of $11 on this stock.
The stock price of Editas Medicine Inc [EDIT] has been fluctuating between $5.11 and $11.91 over the past year. Currently, Wall Street analysts expect the stock to reach $21 within the next 12 months. Editas Medicine Inc [NASDAQ: EDIT] shares were valued at $5.47 at the most recent close of the market. An investor can expect a potential return of 283.91% based on the average EDIT price forecast.
Analyzing the EDIT fundamentals
The Editas Medicine Inc [NASDAQ:EDIT] reported sales of 78.12M for trailing twelve months, representing a surge of 818.74%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -2.1%, Pretax Profit Margin comes in at -1.96%, and Net Profit Margin reading is -1.92%. To continue investigating profitability, this company’s Return on Assets is posted at -0.3, Equity is -0.42 and Total Capital is -0.38. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.23 points at the first support level, and at 4.99 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.69, and for the 2nd resistance point, it is at 5.91.
Editas Medicine Inc [EDIT] reported earnings per share of -$0.23 for its fiscal quarter that ended on 12/31/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.54/share, meaning a difference of $0.31 and a surprise factor of 57.40%. By comparison, the stated earnings for the previous quarter ended on 9/30/2023 were -$0.55 per share as compared to estimates of -$0.57 per share, a difference of $0.02 representing a surprise of 3.50%.
Ratios To Look Out For
It’s worth pointing out that Editas Medicine Inc [NASDAQ:EDIT]’s Current Ratio is 5.39. Further, the Quick Ratio stands at 5.39, while the Cash Ratio is 1.96. Considering the valuation of this stock, the price to sales ratio is 5.76, the price to book ratio is 1.28.
Transactions by insiders
Recent insider trading involved O’Neill Gilmore Neil, CEO, that happened on Mar 05 ’24 when 77824.0 shares were sold. SVP, CHIEF MEDICAL OFFICER, Mei Baisong completed a deal on Mar 04 ’24 to sell 20327.0 shares. Meanwhile, EVP, CBO AND CTO Eaton Bruce sold 103.0 shares on Dec 05 ’23.
